Trial · NCT07205107
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Satisfaction at Week-12 as assessed by DermSat-7 | Week 12 | To describe treatment satisfaction of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel at Week-12 in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Treatment Satisfaction at Week-4, Week-8 and Week-20 as assessed by DermSat-7 | Week 4, Week 8 and Week 20 | To describe treatment satisfaction of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel at Week-4, Week-8 and Week-20 in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Change from Baseline in Treatment Satisfaction at Week-12 as assessed by DermSat-7 | Baseline and Week-12 | To describe change in treatment satisfaction at Week-12 following clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel initiation in patients with acne vulgaris in Canadian routine clinical practice, using mean DermSat-7 domain scores. The DermSat-7 is a dermatology-specific, 7-item questionnaire used to assess patient satisfaction with treatment across three domains: effectiveness, convenience, and overall satisfaction. Domain scores are transformed to a linear 0-100 scale, with higher scores indicating greater satisfaction. |
| Secondary | Treatment Adherence at Week-4, Week-8, Week-12, and Week-20 | From Baseline to Week-20 | To describe treatment adherence to clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as captured in a daily electronic diary using percentage of patients who achieve at least 80% treatment adherence at Week-4, Week-8, Week-12, and Week-20 from treatment initiation. |
| Secondary | Treatment Effectiveness as assessed by mean change from baseline in Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by mean change in IGA score at Week-12 and Week-20 from baseline. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by mean Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by mean IGA score at baseline, Week-12, and Week-20. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by percentage of patients achieving at least a 1-grade improvement in Investigator Global Assessment (IGA) score | Baseline, Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by the percentage of patients who have achieved at least a 1-grade improvement at Week-12 and Week-20 from baseline. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Treatment Effectiveness as assessed by number and percentage of patients achieving a score of 0 to 1 in Investigator Global Assessment (IGA) score | Week-12, and Week-20 | To describe the effectiveness of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, as assessed by number and percentage of patients who achieve IGA = 0 to 1 at Week-12 and Week-20. The IGA is a 5-point scale (0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe), with higher scores indicating worse acne severity. |
| Secondary | Safety and Tolerability | From baseline to Week-20 | To describe the safety and tolerability of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in patients with acne vulgaris in Canadian routine clinical practice, with number and percentage of adverse events (AEs) and serious AEs (SAEs) reported over 20 weeks, and number and percentage of patients who discontinued due to an AE or SAE at Week-20. |
| Secondary | Health State Utility as assessed by Health Utility Index 2 (HUI2) | Baseline, Week-12, and Week-20 | To describe the health state utility scores in patients with acne vulgaris treated with clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in Canadian routine clinical practice, as per percentage change in Health Utility Index 2 (HUI2) score at Week-12 and Week-20 from baseline, and mean HUI2 score at baseline, Week-12, and Week-20. |
| Other | Utilization Patterns of Cleanser, Moisturizer, and Sun Protectant | From Baseline to Week 20 | To describe the utilization patterns of cleanser, moisturizer, and sun protectant in patients with acne vulgaris treated with clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel in Canadian routine clinical practice, as captured in a daily electronic diary. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07205107/registered